Sanitary mastectomy with axillar dissection I and II in advanced breast cancer
Keywords:
MASTECTOMY, BREAST NEOPLASMS, CARCINOMA, DUCTAL, BREAST.Abstract
Introduction: only a few studies provide solid knowledge about the usefulness of sanitary mastectomy with axillary dissection I and II in advanced breast cancer.
Objective: to characterize the behavior of patients with sanitary mastectomy with axillary dissection I and II locally advanced breast cancer at the “María Curie” Provincial Teaching Hospital.
Methods: an observational descriptive and transversal study was carried out on January 2022 to January 2023, where the universe was composed by 50 patients and the sample was made up of 30 patients based on non-probabilistic sampling; they met the selection criteria during the aforementioned period. Data processing was carried out in the SPSS program.
Results: there was a greater frequency if the group 55 to 59 years old. Regarding skin color, there was a predominance of white skin. According to the histological type, the most frequent was infiltrating ductal carcinoma. According to the molecular subtype, there was a predominance of luminal B with HER negative and patients without immunohistochemistry results, which is why this is established as an invaluable tool.
Conclusions: it was possible to characterize the behavior of patients with sanitary mastectomy with axillary dissection I and II in locally advanced breast cancer at the at the “María Curie” Provincial Teaching Hospital from January 2022 to January 2023.
Downloads
References
1. Naciones Unidas. El cáncer mató a diez millones de personas en 2020, la mayoría en países de renta baja y media [Internet]. Naciones Unidas; Feb 2021. [citado 29/09/2023]. Disponible en: https://news.un.org/es/story/2021/02/1487492
2. López Cuevas ZC, González Ortega JM, Amador García RA, Lorenzo Rivera O, Herrera Fernández L, Bello Ávila LB. Cáncer de mama en mujeres jóvenes. Presentación de dos casos. Rev Med Electrón [Internet]. 2018 [citado 29/09/2023]; 40(4): 1186-1196. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_abstract&pid=S1684-18242018000400025&lng=pt&nrm=iso
3. Infomed. Anuario Estadístico de Cuba. 2021 [Internet]. La Habana. Infomed; 2021 [citado 29/09/2023]: 10p. Disponible en: https://temas.sld.cu/estadisticassalud/
4. Torres Ávila R. Cáncer de mama avanzado. Recurrencia locorregional. Centro Oncológico Territorial Holguín. 2020 a 2022. [Tesis]. Hospital Universitario Vladimir Ilich Lenin; 2022 [citado 29/09/2023]. Disponible en: https://tesis.hlg.sld.cu/index.php?P=FullRecord&Resourceld=2868
5. Ramírez Valle M, García Montesino G. Cáncer de mama invasivo según subtipos moleculares en la provincia Pinar del Río. Rev. Ciencias Médicas de Pinar del Río [Internet]. 2020 [citado 29/09/2023]; 24(5): e4362. Disponible en: http://www.scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-31942020000500015
6. Sánchez J, Díaz S, Guzmán L, González D, Quiroga Echeverri A, López D. Quimioterapia neoadyuvante en pacientes con cáncer de mama localmente avanzado, basada en el esquema ciclofosfamida, doxorrubicina, taxanos con o sin trastuzumab, de acuerdo con la sobreexpresión de HER2. Rev. Col. Hematol. Oncol [Internet]. 2020 [citado 29/09/2023]; 7(1): 34-42. Disponible en: https://revista.acho.info/index.php/acho/article/view/18
7. Reyes Cáceres JL. Sobrevida libre de enfermedad en pacientes con cáncer de mama en estadio localmente avanzado ue recibieron tratamiento neoadyuvante de acuerdo a la respuesta patológica [Tesis]. UCE; 2022 [citado 29/09/2023]. Disponible en: https://www.dspace.uce.edu.ec/entities/publication/a9561ea5-aa5e-4819-9c25-50bd51f7d9c9
8. López Sánchez I, Casado Méndez PR, Santos Fonseca RS, Méndez Jiménez O, Estrada Sosa R, Guzmán González AJ. Prevalencia de factores de riesgo del cáncer de mama en población rural femenina. AMC [Internet]. 2019 [citado 29/09/2023]; 23(5): 563-572. Disponible en: http://www.revistaamc.sld.cu/index.php/amc/article/view/6422/3412
9. Ramírez Torres N. Asociando factores pronósticos con resultados clínicos en cáncer de mama localmente avanzado. Rev. Med. Instituto Mexicano de Seguro Social [Internet]. 2022 [citado 29/09/2023]; 61(1): 88-98. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10395981/
10. Osorio Bazar N, Bello Hernández C, Vega Bazar L. Factores de riesgo asociados al cáncer de mama. Rev. Cub. Med. Gen. Integr [Internet]. 2020 [citado 30/09/2023]; 36(2): e1147. Disponible en: http://www.scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21252020000200009
11. Ramón Concepción I, Soriano García JL, Valenciano Estenoz ML, Batista Albuerne N, Lima Pérez M, Duvergel Calderín D, et al. Supervivencia de pacientes con cáncer mamario temprano HER2 positivo tratadas con trastuzumab endovenoso en adyuvancia. Rev. Cub. de Oncología [Internet]. 2021 [citado 30/09/2023]; 19(1). Disponible en: http://www.revoncologia.sld.cu/index.php/onc/article/view/91
12. American Cancer Society. Factores de riesgo del cáncer de seno que usted no puede cambiar [Internet]. American Cancer Society; 2019 [citado 30/09/2023]: 8 p. Disponible en: https://www.cancer.org/es/cancer/cancer-de-seno/riesgos-y-prevencion/factores-de-riesgo-del-cancer-de-seno-que-usted-no-puede-cambiar.html
13. Carbón Tamayo MA, León Rodríguez Y, Chirino Rodríguez G, Cairo Báez JN, Gálvez Chávez JC, Morales Sanabria J. Cierre de zona cruenta secundaria a mastectomía sanitaria por cáncer de mama localmente avanzado [Internet]. Jornada de Temas Terminados. Convención Científico-Técnica XXXII Aniversario Hospital Hermano Ameijeiras; 2020 [citado 30/09/2023]. Disponible en: http://convencionhha2020.sld.cu/index.php/JTT/2020/paper/view/86/360
14. Hoffman J, Fejerman L, Hu D, Huntsman S, Li M, John EM, et al. Identification of novel common breast cancer risk variants at the 6q25 locus among Latinas. Breast Cancer Research [Internet]. 2019 [citado 30/09/2023]; 21(3). Disponible en: https://www.breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-018-1085-9
15. Alcaide Lucena M, Rodríguez González CJ, de Reyes Lartategui S, Gallart Aragón T, Sánchez Barrón MT, García Rubio J, et al. Clasificación actual del cáncer de mama. Implicación en el tratamiento y pronóstico de la enfermedad. Cir. Andal [Internet]. 2021 [citado 30/09/2023]; 32(2): 155-59. Disponible en: https://dialnet.unirioja.es/descarga/articulo/8962351.pdf
Downloads
Published
How to Cite
Issue
Section
License
Authors who have publications with this journal agree to the following terms: Authors will retain their copyrights and grant the journal the right of first publication of their work, which will be publication of their work, which will be simultaneously subject to the Creative Commons Attribution License (CC-BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g.: deposit it in an institutional telematic archive or publish it in a volume). Likewise, and according to the recommendations of the Medical Sciences Editorial (ECIMED), authors must declare in each article their contribution according to the CRediT taxonomy (contributor roles). This taxonomy includes 14 roles, which can be used to represent the tasks typically performed by contributors in scientific academic production. It should be consulted in monograph) whenever initial publication in this journal is indicated. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which may produce interesting exchanges and increase citations of the published work. (See The effect of open access). https://casrai.org/credit/
